Genome profiling of ERBB2-amplified breast cancers

被引：0
|
作者：
Fabrice Sircoulomb
Ismahane Bekhouche
Pascal Finetti
José Adélaïde
Azza Ben Hamida
Julien Bonansea
Stéphane Raynaud
Charlène Innocenti
Emmanuelle Charafe-Jauffret
Carole Tarpin
Farhat Ben Ayed
Patrice Viens
Jocelyne Jacquemier
François Bertucci
Daniel Birnbaum
Max Chaffanet
机构：
[1] Institut Paoli-Calmettes,Marseille Cancer Research Center, UMR891 Inserm
[2] Department of Molecular Oncology,Department of BioPathology
[3] Institut Paoli-Calmettes,Department of Medical Oncology
[4] Institut Paoli-Calmettes,Department of Medical Oncology
[5] Université de la Méditerranée,undefined
[6] Salah Azaiz Institute,undefined
来源：
BMC Cancer | / 10卷
关键词：
Epidermal Growth Factor Receptor; Estrogen Receptor; Trastuzumab; Copy Number Gain; Copy Number Aberration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Genome profiling of ERBB2-amplified breast cancers
    Sircoulomb, Fabrice
    Bekhouche, Ismahane
    Finetti, Pascal
    Adelaide, Jose
    Ben Hamida, Azza
    Bonansea, Julien
    Raynaud, Stephane
    Innocenti, Charlene
    Charafe-Jauffret, Emmanuelle
    Tarpin, Carole
    Ben Ayed, Farhat
    Viens, Patrice
    Jacquemier, Jocelyne
    Bertucci, Francois
    Birnbaum, Daniel
    Chaffanet, Max
    BMC CANCER, 2010, 10
  • [2] Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
    Shiu, K-K
    Wetterskog, D.
    Mackay, A.
    Natrajan, R.
    Lambros, M.
    Sims, D.
    Bajrami, I.
    Brough, R.
    Frankum, J.
    Sharpe, R.
    Marchio, C.
    Horlings, H.
    Reyal, F.
    van der Vijver, M.
    Turner, N.
    Reis-Filho, J. S.
    Lord, C. J.
    Ashworth, A.
    ONCOGENE, 2014, 33 (05) : 619 - 631
  • [3] Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
    K-K Shiu
    D Wetterskog
    A Mackay
    R Natrajan
    M Lambros
    D Sims
    I Bajrami
    R Brough
    J Frankum
    R Sharpe
    C Marchio
    H Horlings
    F Reyal
    M van der Vijver
    N Turner
    J S Reis-Filho
    C J Lord
    A Ashworth
    Oncogene, 2014, 33 : 619 - 631
  • [4] AKT signaling in ERBB2-amplified breast cancer
    Carmona, F. Javier
    Montemurro, Filippo
    Kannan, Srinivasaraghavan
    Rossi, Valentina
    Verma, Chandra
    Baselga, Jose
    Scaltriti, Maurizio
    PHARMACOLOGY & THERAPEUTICS, 2016, 158 : 63 - 70
  • [5] Genetic alterations in ERBB2-amplified breast carcinomas
    Isola, J
    Chu, L
    DeVries, S
    Matsumura, K
    Chew, K
    Ljung, BM
    Waldman, FM
    CLINICAL CANCER RESEARCH, 1999, 5 (12) : 4140 - 4145
  • [6] Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
    D Wetterskog
    K-K Shiu
    I Chong
    T Meijer
    A Mackay
    M Lambros
    D Cunningham
    J S Reis-Filho
    C J Lord
    A Ashworth
    Oncogene, 2014, 33 : 966 - 976
  • [7] Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
    Wetterskog, D.
    Shiu, K-K
    Chong, I.
    Meijer, T.
    Mackay, A.
    Lambros, M.
    Cunningham, D.
    Reis-Filho, J. S.
    Lord, C. J.
    Ashworth, A.
    ONCOGENE, 2014, 33 (08) : 966 - 976
  • [8] EGFR-dependent matriptase activation in ErbB2-amplified breast cancer
    Gaymon, Darius
    CANCER RESEARCH, 2018, 78 (13)
  • [9] MITOCHONDRIAL DNA COPY NUMBER INSTABILITY IN ERBB2-AMPLIFIED BREAST CANCER TUMORS
    Ebrahimi, Elmira
    Almasi-Hashiani, Amir
    Ghaffari, Kimia
    Shirkoohi, Reza
    EXCLI JOURNAL, 2018, 17 : 149 - 158
  • [10] TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells
    Roslan, Nuruliza
    Bieche, Ivan
    Bright, Robert K.
    Lidereau, Rosette
    Chen, Yuyan
    Byrne, Jennifer A.
    MOLECULAR CARCINOGENESIS, 2014, 53 (10) : 807 - 819
12345